Browsing by Author Robert, Caroline

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 23  next >
Issue DateTitleAuthor(s)Citation
2014Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trialKefford, Richard (Rick); Boasberg, Peter; Chmielowski, Bartosz; Daud, Adil; Dronca, Roxana; Ebbinghaus, Scot; Elassaiss-Schaap, Jeroen; Gangadhar, Tara C.; Gergich, Kevin; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Iannone, Robert; Joseph, Richard W.; Joshua, Anthony M.; Kang, Peter; Li, Xiaoyun; Mateus, Christine; Patnaik, Amita; Postow, Michael; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Western Clinical School: Westmead Millennium InstituteAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial, The Lancet, vol.384, 9948, 2014,pp 1109-1117
2017Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialLong, Georgina; Arance, Ana; Chiarion-Sileni, Vanna; Davies, Michael; Del Vecchio, M; Flaherty, Keith; Grob, Jean-Jacques; Hogg, David; Huang, Yingjie; Lebbe, Celeste; Lesimple, Thierry; Márquez-Rodas, Ivan; Meyer, Nicolas; Mookerjee, Bijoyesh P; Mortier, Laurent; Moschos, S; Robert, Caroline; Saiag, Philippe; Thomas, Luc; Zhang, Ying; Northern Clinical School: MedicineDabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial, The Lancet Oncology, vol.18, 7, 2017,pp 863-873
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2016Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III checkmate 066 studyLong, Georgina; Abernethy, Amy P; Ascierto, Paolo; Atkinson, V; Coon, C.; Dastani, I; Gilloteau, I; Hassel, Jessica; Robert, Caroline; Rutkowski, Piotr; Savage, Kerry; Taylor, F.; Waxman, I M; Northern Clinical School: MedicineEffect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III checkmate 066 study, Annals of Oncology, vol.27, 10, 2016,pp 1940-1946
2016Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with PembrolizumabHersey, Peter; Daud, Adil; et al, Various; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Kefford, Richard F.; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Northern Clinical School: SurgeryEvaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab, Journal of Clinical Oncology, vol.34, 13, 2016,pp 1510-1517
2016Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsLong, Georgina; Davies, Michael; Flaherty, Keith; Grob, Jean-Jacques; Lane, Stephen; Legenne, Philippe; Mak, Carmen; Nathan, Paul; Ribas, Antoni; Robert, Caroline; Schadendorf, D; Northern Clinical School: MedicineFactors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials, The Lancet Oncology, vol.17, 12, 2016,pp 1743-1754
2013Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced MelanomaKefford, Richard (Rick); Chiarion-Sileni, Vanna; Eggermon, Alexander; et al, Various; Grob, Jean Jacques; Mackiewicz, Jacek; Mortier, Laurent; O'Day, Steven; Robert, Caroline; Schachter, Jacob; Testori, Alessandro; Western Clinical School: Westmead Millennium InstituteFinal Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma, Journal of Clinical Oncology, vol.31, 9, 2013,pp 1211-1218
2015Improved overall survival in melanoma with combined dabrafenib and trametinibLong, Georgina; Chiarion-Sileni, Vanna; Dummer, R; et al, Various; Grange, Florent; Karaszewska, Boguslawa; Lichinitser, Michael; Mackiewicz, Andrzej; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Schachter, Jacob; Stroiakovski, Daniel; Central Clinical School: The Sydney Cancer CentreImproved overall survival in melanoma with combined dabrafenib and trametinib, New England Journal of Medicine, vol.372, 1, 2015,pp 30-39
2012Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaHersey, Peter; Demidov, Lev; Drummer, Reinhard; et al, Various; Flaherty, Keith; Garbe, Claus; Hassel, Jessica; Milhem, Mohammed; Mohr, P; Nathan, Paul; Robert, Caroline; Rutkowski, Piotr; Northern Clinical School: SurgeryImproved Survival with MEK Inhibition in BRAF-Mutated Melanoma, New England Journal of Medicine, vol.367, 2, 2012,pp 107-114
2017Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialMcNeil, Catriona; Arance, A; Ascierto, Paolo A; Bastholt, Lars; Chiarion-Sileni, Vanna; Del Vecchio, Michele; et al, Various; Hamid, Omid; Lebbe, Celeste; Mackiewicz, Andrzej; Robert, Caroline; Rutkowski, Piotr; Central Clinical School: MedicineIpilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial, The Lancet Oncology, vol.18, 5, 2017,pp 611-622
2017Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical TrialsLong, Georgina; Atkinson, V; Dummer, R; et al, Various; Grob, Jean Jacques; Larkin, James; Márquez-Rodas, Ivan; McNeil, Catriona M.; Robert, Caroline; Schadendorf, Dirk; Schmidt, Henrik; Weber, Jeffrey; Northern Clinical School: MedicineNivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials, JAMA Oncology, vol.3, 11, 2017,pp 1511-1519
2015Nivolumab in Previously Untreated Melanoma without BRAF MutationLong, Georgina; Brady, Ben; Dutriaux, Caroline; et al, Various; Hassel, Jessica; Hernberg, Micaela; Kalinka-Warzocha, Ewa; Maio, Michele; McNeil, Catriona; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Savage, Kerry; Central Clinical School: The Sydney Cancer CentreNivolumab in Previously Untreated Melanoma without BRAF Mutation, The New England Journal of Medicine, vol.372, 4, 2015,pp 320-330
2015Pembrolizumab versus ipilimumab in advanced melanomaCarlino, Matteo; Long, Georgina; Arance, Ana; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lorigan, Paul; Lotem, Michal; McNeil, Catriona; Mortier, Laurent; Neyns, Bart; Robert, Caroline; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentrePembrolizumab versus ipilimumab in advanced melanoma, The New England Journal of Medicine, vol.372, 26, 2015,pp 2521-2532
2017Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanomaCarlino, Matteo; Kefford, Richard (Rick); Arance, Ana; Delord, Jean-Pierre; et al, Various; Kudchakar, Ragini; Mahipal, Amit; McArthur, Grant A.; Nyakas, Marta; Robert, Caroline; Sullivan, Ryan; Yamada, Yasuhide; Westmead Clinical School: Medicine; Westmead Clinical School: MedicinePhase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma, Clinical Cancer Research, vol.23, 18, 2017,pp 5339-5348